Back in 2023, the US held the top spot in the worldwide prescription pharma space with a huge 43.5% share. This strong lead comes from a solid healthcare setup, supportive regulations, innovative reimbursement systems, and heavy R&D spending. Rubicon Research has been in this space and will be launching its IPO soon.
IIFL Securities, Axis Capital, and JM Financial will be managing the Rubicon Research IPO and Link Intime will be registering the IPO. Check the allotment status.
For a better review, go through the Rubicon Research DRHP.
Note: For Rubicon Research Private Limited IPO, 50% of the IPO shares will become tradable 30 days after allotment, and the remaining portion will be released from lock-in after 90 days.
The company profile of Rubicon Research is given below:
Let's see what you should know about the Rubicon Research Limited IPO.
Rubicon Research Pvt Ltd took its first step towards the IPO by filing papers with SEBI and the stock exchange on July 31, 2024. The approval was received on October 31, 2024.
Here are the essential risks and strengths of Rubicon Research:
Strengths
Big Presence in the US: The company already has a strong setup in America, selling both branded and generic products with ease.
Fresh Ideas from R&D: With research teams in India and Canada, they keep coming up with new products while cutting back on outside help.
Popular Products in Hand: Seven of their medicines enjoy more than 25% market share in the US.
Trusted by Regulators: They’ve cleared tough checks from the US FDA and other global bodies.
Risks
Over-Reliance on the US: Most of their earnings come from America, so any slowdown there could hurt the business quickly.
Pharma Rules are Tough: If there’s a recall, inspection problem, or plant shutdown, it could shake things up in a big way.
R&D is a Gamble: Not every new idea turns into a winning product, and that risk can slow down growth.
Money Matters: Loan conditions and currency ups and downs might squeeze profits if not handled carefully.
As of 30 September 2025, the Rubicon Research IPO GMP hasn’t been shared yet. Still, you can check the company profile and final prospectus to get a clear picture before deciding.
Also, check the latest GMP here.
You must also see the live subscription numbers. Apply today.
1. How is the Rubicon Research Limited IPO review?
Rubicon Research is seen as a pharmaceutical company, with expansion capital as a key objective. For the latest sentiment, you can look for the GMP updates.
2. What is the Rubicon Research IPO date?
The open and the closing date of Rubicon Research IPO is from 09th October to 13th October. But one can monitor live subscription details in real time.
3. What is the Rubicon Research IPO price?
The share price is unavailable as per the latest Rubicon Research IPO news. The final issue price will fall within this range. Also, don't forget to check the allotment and Rubicon Research turnover details.
4. Should I use a demat account to bid for the Rubicon Research IPO?
Yes, a demat account is required to bid for the Rubicon Research IPO. Click here to get the ultimate list of the top demat account providers.
